Persisting inflammation and chronic immune activation but intact cognitive function in HIV-infected patients after long-term treatment with combination antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 3, 2013, Pages 272-279

  Pedersen, Karin K ^a   Pedersen, Maria ^a   Gaardbo, Julie C ^a   Ronit, Andreas ^a   Hartling, Hans J ^a   Bruunsgaard, Helle ^a   Gerstoft, Jan ^a   Ullum, Henrik ^a   Nielsen, Susanne D ^a  

^a University of Copenhagen   (Denmark)

Author keywords

Flow cytometry; HIV infection; Immune activation; Inflammation; Neurocognitive function

Indexed keywords

BETA 2 MICROGLOBULIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ATTENTION; CD4 LYMPHOCYTE COUNT; COGNITION; COMBINATION ANTIRETROVIRAL THERAPY; CONTROLLED STUDY; DEPRESSION; EXECUTIVE FUNCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INFLAMMATION; INFORMATION PROCESSING; LANGUAGE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BETA 2-MICROGLOBULIN; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COGNITION; COGNITION DISORDERS; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VIRUS REPLICATION;

EID: 84880230828     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318289bced     Document Type: Article

References (72)

1. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004;157:3-10.
2. Lescure FX, Omland LH, Engsig FN, et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis. 2011; 52:235-243.
3. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69: 1789-1799.
4. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsycholog-ical impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre-and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neuro-virol. 2004;10:350-357.
5. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007; 21:1915-1921.
6. Simoni JM, Safren SA, Manhart LE, et al. Challenges in addressing depression in HIV research: assessment, cultural context, and methods. AIDS Behav. 2010;15:376-388.
7. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neuro-cognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087-2096.
8. Gandhi NS, Moxley RT, Creighton J, et al. Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder. HIV Ther. 2010;4:371-379.
9. Mitrushina M, Boone KB, Razani J, et al. Handbook of Normative Data for Neuropsychological Assessment. 2nd ed. New York, NY: Oxford University Press; 2005.
10. Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry. 2008; 20:33-47.
11. Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005;11:265-273.
12. Ryan EL, Morgello S, Isaacs K, et al. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology. 2004;62:957-962.
13. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 1999;52:607-613.
14. Ferrando S, van Gorp W, McElhiney M, et al. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS. 1998;12:F65-F70.
15. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses. 2008;24:1301-1307.
16. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25:1747-1751.
17. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16.
18. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS. 2011;25:1385-1394.
19. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859-870.
20. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
21. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543.
22. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881-1888.
23. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.
24. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. 2008;22:2409-2418.
25. Bruunsgaard H, Andersen-Ranberg K, Jeune B, et al. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci. 1999;54:M357-M364.
26. Krabbe KS, Mortensen EL, Avlund K, et al. Genetic priming of a proin-flammatory profile predicts low IQ in octogenarians. Neurobiol Aging. 2009;30:769-781.
27. Schram MT, Euser SM, de Craen AJ, et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc. 2007;55:708-716.
28. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol. 2004; 61:668-672.
29. Weaver JD, Huang MH, Albert M, et al. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology. 2002; 59:371-378.
30. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73:768-774.
31. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology. 2004;63:2084-2090.
32. Ragin AB, Wu Y, Ochs R, et al. Biomarkers of neurological status in HIV infection: a 3-year study. Proteomics Clin Appl. 2010;4:295-303.
33. Lyons JL, Uno H, Ancuta P, et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr. 2011;57:371-379.
34. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008;3:e2516.
35. Pedersen M, Pedersen KK, Bruunsgaard H, et al. Cognitive functions in middle aged individuals are related to metabolic disturbances and aerobic capacity: a cross-sectional study. PLoS One. 2012;7:e51132.
36. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251.
37. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
38. Bech P, Rasmussen NA, Olsen LR, et al. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. J Affect Disord. 2001;66:159-164.
39. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed. New York, NY: Oxford University Press; 2004.
40. Hartmann P, Jørgensen K, Mortensen EL. WAIS-IIIDK-Wechsler Adult Intelligence Scale-III. Copenhagen, Denmark: Dansk Psykologisk For-lag; 2007.
41. Nelson H, Willison J. National Adult Reading Test (NART). Test Manual. Windsor, UK: NFER-Nelson; 1982.
42. Crawford JR, Moore JW, Cameron IM. Verbal fluency: a NART-based equation for the estimation of premorbid performance. Br J Clin Psychol. 1992;31(pt 3):327-329.
43. Franzen MD, Burgess EJ, Smith-Seemiller L. Methods of estimating premorbid functioning. Arch Clin Neuropsychol. 1997;12:711-738.
44. McCutchan JA, Wu JW, Robertson K, et al. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS. 2007;21:1109-1117.
45. Skinner S, Adewale AJ, DeBlock L, et al. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to anti-retroviral therapy. HIV Med. 2009;10:246-252.
46. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neuro-cognitive disorders: are we overestimating the real prevalence? BMC Infect Dis. 2011;11:356.
47. Torti C, Foca E, Cesana BM, et al. Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction? BMC Med. 2011; 9:138.
48. Garvey L, Surendrakumar V, Winston A. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials. 2011;12:333-338.
49. Sherr L, Clucas C, Harding R, et al. HIV and depression-a systematic review of interventions. Psychol Health Med. 2011;16:493-527.
50. Gonzalez JS, Batchelder AW, Psaros C, et al. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58:181-187.
51. Rabkin JG. HIV and depression: 2008 review and update. Curr HIV/AIDS Rep. 2008;5:163-171.
52. Benton TD. Depression and HIV/AIDS. Curr Psychiatry Rep. 2008;10: 280-285.
53. Gannon P, Khan MZ, Kolson DL. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol. 2011;24:275-283.
54. Autran B, Carcelain G, Li TS, et al. Positive effects of combined anti-retroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
55. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid beta 2-micro-globulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS. 1992;6:461-465.
56. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17:118-123.
57. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396:690-695.
58. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 2000;95:249-255.
59. Kolte L, Dreves AM, Ersboll AK, et al. Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2002;185:1578-1585.
60. Lane HC. Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation. Top HIV Med. 2010;18:2-6.
61. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788-1795.
62. Ostrowski SR, Gerstoft J, Pedersen BK, et al. Impaired production of cytokines is an independent predictor of mortality in HIV-1-infected patients. AIDS. 2003;17:521-530.
63. Sidenius N, Sier CF, Ullum H, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood. 2000;96: 4091-4095.
64. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antire-troviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359-1366.
65. Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretrovi-ral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004;56:416-423.
66. Ellis RJ, Moore DJ, Childers ME, et al. Progression to neuropsycholog-ical impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol. 2002;59:923-928.
67. Marra CM, Lockhart D, Zunt JR, et al. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology. 2003;60:1388-1390.
68. Letendre SL, Ellis RJ, Ances BM, et al. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18:45-55.
69. Cardenas VA, Meyerhoff DJ, Studholme C, et al. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol. 2009;15:324-333.
70. Sevigny JJ, Albert SM, McDermott MP, et al. An evaluation of neuro-cognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol. 2007;64:97-102.
71. Woods SP, Moore DJ, Weber E, et al. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009;19:152-168.
72. McCombe J, Vivithanaporn P, Gill M, et al. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care. HIV Med. 2012;14:99-107.